The FDA’s Pharmacy Compounding Advisory Committee wrapped a two-day meeting July 24, ultimately recommending six of the seven peptides under review — BPC-157, KPV, TB-500, MOTs-C, epitalon and Semax — for inclusion on the agency’s Section 503A Bulk Drug Substances List. The panel rejected the seventh, emideltide, siding with FDA scientists’ concerns that the evidence behind it was too thin to support even a compounding pathway.
Five things to know:
1. Emideltide fell short on both indications it was reviewed for. The clinical studies backing narcolepsy and opioid withdrawal uses relied on an intravenous route, while the peptide itself was proposed for subcutaneous injection, a mismatch the committee flagged. The supporting evidence amounted to a single case report for narcolepsy and two small, uncontrolled studies for opioid withdrawal, and FDA noted that established, approved treatments already exist for both conditions.
2. For BPC-157, KPV and TB-500, eight members voted yes, six voted no, and one abstained. MOTS-C saw seven members vote yes, five vote no, and two abstain. Epitalon and Semax, reviewed on the meeting’s second day, followed a similar breakdown. Committee members who voted yes largely framed their votes around harm reduction, arguing that keeping these substances off the list would simply push more patients toward black-market suppliers with no physician involvement and no verified contents. Members who voted no pushed back on that framing directly, arguing during public testimony that market size and consumer demand aren’t a substitute for clinical evidence, and that legitimizing a product because it’s already popular sets a troubling precedent. Each substance is tied to a specific proposed use, not a blanket approval. For instance, BPC-157 was under review for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTs-C for obesity and osteoporosis. Emideltide is under review for opioid withdrawal, chronic insomnia and narcolepsy, and Semax for cerebral ischemia, migraine and trigeminal neuralgia.
3. The vote runs directly against FDA staff’s own recommendation. Ahead of the meeting, FDA’s own briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. The American Pharmacists Association is siding with FDA’s staff for now. In a July 9 comment letter to the committee, APhA said it supports FDA’s recommendation against adding any of the seven substances to the list at this time, barring new evidence presented during the comment period or at the meeting. The group’s reasoning centers on a few points. Without peer-reviewed clinical data, pharmacists lack the evidence to counsel patients on dosing, drug interactions or side effects. Adverse events tied to gray-market peptides are also difficult to trace back to the substance itself versus manufacturing contaminants, since sourcing is often unregulated. The letter also flags that large-scale compounded peptide production could fall outside Drug Supply Chain Security Act traceability requirements, which don’t typically apply to compounded preparations.
4. The panel reviewing these peptides has drawn its own scrutiny. At the beginning of the month, the roster leaned toward physicians who run wellness, longevity and regenerative medicine clinics rather than the university researchers who staffed prior compounding panels, and at least one appointed member has separately promoted BPC-157 to his own social media following. However, the FDA has since added eight temporary voting members to the committee. The newest members include clinical researchers, professors of medicine, and pain and substance use experts. The additions came after criticism that the earlier roster was stacked with members tied to peptide-related businesses and clinics, although the FDA hasn’t said whether that criticism prompted the change.
5. A “yes” is still a long way from a pharmacy shelf. PCAC’s recommendation is advisory, not binding. The recommendations still need FDA sign-off, and the agency’s own reviewers have already gone on record against all seven substances. A second PCAC meeting covering five more peptides, including GHK-Cu and Melanotan II, is expected before the end of February 2027.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
